Vinay Prasad, who abruptly stepped down as head of the FDA's Center for Biologics Evaluation and Research (CBER), is set to return to his leadership role at the FDA following an internal request. His departure weeks earlier followed escalating tensions related to Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy and external political pushback. His return signals ongoing challenges and shifts within the agency overseeing vaccines, gene therapy, and blood products amidst regulatory scrutiny.